BARI 2D STUDY

巴里 2D 研究

• 批准号: 7603170
• 负责人: WILLIAM J ROGERS
• 金额: $ 5.07万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603170
• 关键词: Clinical; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Coronary; Coronary Arteriosclerosis; Funding; Glycosylated hemoglobin A; Grant; Institution; Insulin; Medical; Non-Insulin-Dependent Diabetes Mellitus; Patients; Percutaneous Transluminal Coronary Angioplasty; Research; Research Personnel; Resources; Source; Treatment Protocols; United States National Institutes of Health; follow-up; glycemic control; mortality

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The BARI 2D trial is an NIH-sponsored, investigator-initiated, multicenter clinical trial whose objective is to determine, in patients with Type 2 diabetes mellitus and stable, documented coronary artery disease, whether 5-year mortality is lower with (1) a strategy of initial coronary revascularization (either PTCA or CABG) combined with intensive medical therapy vs intensive medical therapy alone, and (2) glycemic control achieved by an insulin sensitizaton regimen vs an insulin provision regimen (both to a target HbA1c level of <7.0%). UAB is one of about 50 clinical centers participating in this trial of about 2400 patients with follow-up of 5-7 years.

这个子项目是众多研究子项目之一